TRINITY BIOTECH Zahlen 3.Quartal - 500 Beiträge pro Seite

[SaintVenant]

Trinity Biotech Announces 43% Increase in Third Quarter Profit to US$1.735m and 15% Revenue Growth to
US$7.60m -- 7:26 AM EDT

DUBLIN, Ireland, Oct 24, 2000 /PRNewswire via COMTEX/ -- Trinity Biotech plc
(Nasdaq: TRIBY) today announced results for the three months and nine months
ended September 30, 2000. Net profit rose 43% to US$1,735k for the third quarter
ended September 30, 2000, compared to US$1,210k for the same period last year.
Revenue grew by 15% to US$7,601k for the third quarter compared to US$6,602k for
the same period last year. Earnings per share grew 6% to 4.54 cents per share
compared to 4.28 cents for the same period last year.

Net profit for the nine months ended September 30, 2000 rose 47% to US$4,737k
compared to US$3,214k for the same period last year. Revenue rose 12% to
US$21,852k for the nine month period compared to US$19,454k for the same period
last year. Earnings per share rose 16% to 13.21 cents per share for the nine
months ended September 30, 2000, compared to 11.41 cents for the same period
last year.

Earnings before interest, tax and amortisation (EBITDA) rose 19% to US$2,095k
for the third quarter and 24% to US$5,925k for the nine months, compared to
US$1,762k and US$4,789k respectively for the same periods last year.

On October 3, 2000, Trinity Biotech announced that it had acquired 33.3% of the
share capital of HiberGen Ltd. for a consideration of $1,300k. HiberGen is an
Irish genomics company, which aims to discover genetic variations of medical
importance and has a broadly enabling and proprietary platform (SNaPIT) both for
this and for use in pharmacogenomic analysis.

Commenting on the results, Maurice Hickey, Chief Financial Officer, said,
"Trinity Biotech had another strong performance in the third quarter with net
profits increasing to US$1,735k. Research and development expenses amounted to
US$834k compared to US$600k for the same period last year. Selling, general and
administrative expenses increased from US$802k in the third quarter last year to
US$1,031k this year reflecting the additional administration costs of Mardx and
increased investment in the sales and marketing area. Trinity Biotech has been
strongly cash generative for the nine months with EBITDA of US$5,925k and, as at
September 30, 2000, the Company had cash balances of US$9,901k and bank debt of
US$3,769k."

Ronan O`Caoimh, Chief Executive Officer, commented, "The third quarter of 2000
produced another solid trading performance. In addition, the quarter was
particularly positive given the successful completion of our investment in
HiberGen Ltd. Through the licences acquired as part of this investment, Trinity
Biotech will be enabled to develop a range of molecular diagnostic tests
complementary to its existing product range."

Finally, Trinity Biotech is pleased to announce that it will be changing its
Nasdaq symbol from TRIBY to TRIB as of the opening of business on November 1,
2000. The change in symbol ensures that Trinity Biotech is on a par with other
companies on the Nasdaq with only four letters in its symbol.

Trinity Biotech develops, manufactures and markets over 100 diagnostic products
for the point-of-care, self-testing and clinical laboratory segments of the
diagnostic market. Trinity Biotech sells worldwide in over 75 countries, through
more than 130 international distributors and strategic partners.

Forward-looking statements in this release are made pursuant to the "safe
harbor" provision of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risks and
uncertainties including, but not limited to, the results of research and
development efforts, the effect of regulation by the United States Food and Drug
Administration and other agencies, the impact of competitive products, product
development commercialisation and technological difficulties, and other risks
detailed in the Company`s periodic reports filed with the Securities and
Exchange Commission.


TRINITY BIOTECH PLC
Consolidated Statement of Operations

(US$000`s except share data)

Three Months Three Months Nine Months Nine Months
Ended Ended Ended Ended
Sept. 30, Sept. 30, Sept. 30, Sept. 30,
2000 1999 2000 1999
(Unaudited) (Unaudited) (Unaudited) (Unaudited)

Revenues 7,601 6,602 21,852 19,454

Cost of goods sold (3,792) (3,601) (11,051) (11,156)
3,809 3,001 10,801 8,298
Research and
development (834) (600) (2,369) (1,694)
Selling, general &
administrative
expenses (1,031) (802) (2,971) (2,285)
Amortisation (218) (203) (656) (602)

Operating profit 1,726 1,396 4,805 3,717

Interest and
other income 145 16 335 54
Interest expense (136) (202) (403) (557)

Net profit 1,735 1,210 4,737 3,214
Earnings per
ordinary
share (in cents) 4.54 4.28 13.21 11.41

Weighted average
number of
ordinary shares
outstanding 38,221,589 28,299,253 35,853,025 28,154,712
Earnings before
interest, tax,
depreciation
and amortisation
(EBITDA) 2,095 1,762 5,925 4,789


TRINITY BIOTECH PLC
Consolidated Balance Sheet

30 September, 31 December,
2000 1999
(Unaudited) (Audited)
US$000`s US$000`s

FIXED ASSETS
Intangible assets 25,163 20,559
Tangible assets 5,264 4,696
30,427 25,255

CURRENT ASSETS
Inventories 10,679 9,511
Debtors and prepayments 8,790 7,212
Cash at bank 9,901 3,064
29,370 19,787

CREDITORS (Amounts falling due within one year) (5,271) (14,234)

NET CURRENT ASSETS 24,099 5,553
TOTAL ASSETS LESS CURRENT LIABILITIES 54,526 30,808

CREDITORS (Amounts falling due
after more than one year) (5,697) (8,086)
48,829 22,722
CAPITAL AND RESERVES
Called up share capital
Class `A` Ordinary shares 547 448
Class `B` Ordinary shares 12 12
Share premium account 71,198 47,864
Currency adjustment (6,932) (4,637)
Profit and loss reserve (15,996) (20,965)
Shareholders` funds - (all equity interests) 48,829 22,722

SOURCE Trinity Biotech plc


CONTACT: Maurice Hickey of Trinity Biotech plc, [phone], or
[e-mail]
(TRIBY)

http://www.prnewswire.com

(C) 2000 PR Newswire. All rights reserved.



KEYWORD: Ireland
INDUSTRY KEYWORD: BIO
MTC
SUBJECT CODE: ERN








TABLE-Trinity Biotech Q3 net up 43 pct -- 7:57 AM EDT

DUBLIN, Oct 24 (Reuters) - Three months to Sept 30, 2000
(million dollars unless stated)
Shr (cents) 4.54 vs 4.28
Net profit 1.74 vs 1.21
Oper profit 1.73 vs 1.40
Revenues 7.6 vs 6.6
EBITDA* 2.10 vs 1.76
*Earnings before interest, tax, depreciation and amortisation.
NOTE - Full name of the Irish diagnostic products
manufacturer is Trinity Biotech Plc .
((Dublin newsroom, [phone], fax [phone],
[e-mail]))

[[KERN]Codex]

Kannsde mal aufhören hier das Board zuzumüllen?!
Es besteht ein großer thread..dort findest du alle Infos!

[Meister Glanz]

ja, hier steht schon öfters mal das gleiche!